[go: up one dir, main page]

PE20020265A1 - CARBOXIALKYLETER - ACAT INHIBITOR COMBINATIONS - Google Patents

CARBOXIALKYLETER - ACAT INHIBITOR COMBINATIONS

Info

Publication number
PE20020265A1
PE20020265A1 PE2001000517A PE2001000517A PE20020265A1 PE 20020265 A1 PE20020265 A1 PE 20020265A1 PE 2001000517 A PE2001000517 A PE 2001000517A PE 2001000517 A PE2001000517 A PE 2001000517A PE 20020265 A1 PE20020265 A1 PE 20020265A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
cholesterol
carboxialkyleter
cycloalkyl
Prior art date
Application number
PE2001000517A
Other languages
Spanish (es)
Inventor
Donna Lee Zobel
Bruce Jeffrey Auerbach
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20020265A1 publication Critical patent/PE20020265A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE a)UN CARBOXIALQUILETER DE FORMULA ( Y1)(R1)(R2)C-(CH2)n-O-(CH2)m-C(Y2)(R3)(R4) DONDE, n Y m SON 2-9; R1, R2, R3, R4 SON ALQUILO C1-C6, ALQUENILO C1-C6, ALQUINILO C1-C6, R1 Y R2 O R3 Y R4 JUNTOS FORMAN CARBOCICLO C3-C6; Y1 E Y2 SON COOH, CHO, TETRAZOL, COOR5; R5 ES ALQUILO C1-C5, ALQUENILO C2-C6, ALQUINILO C2-C6; b)UN INHIBIDOR DE LA ENZIMA ACETIL-COENZIMA A:COLESTEROL ACILTRANSFERASA (ACAT) QUE PREVIENE LA ABSORCION DEL COLESTEROL DIETARIO EN EL FLUJO SANGUINEO O LA REABSORCION DE COLESTEROL QUE PREVIAMENTE HA SIDO LIBERADO EN EL INTESTINO A TRAVES DE LA PROPIA ACCION REGULADORA DEL CUERPO; DE FORMULA R1-X-S(=O)2-NR-C(=O)-Y-R2; DONDE X E Y SON S, O; (CR'R")n; n ES 1-4; R' Y R" SON H, ALQUILO, ALCOXI, HALOGENO, OH, ACILOXI, CICLOALQUILO, FENILO R' Y R" FORMAN ESPIROCICLOALQUILO, CARBONILO; UNO DE X E Y ES (CR'R")n; Y R' Y R" SON H; n ES 1; R1 Y R2 SON ARILO; R ES H, ALQUILO C1-C8, BENCILO; R1 Y R2 SON FENILO, FENOXI, NAFTILO, ARILALQUILO, ALQUILO C1-C20, ADAMANTILO, CICLOALQUILO C3-C6; SIENDO COMPUESTOS PREFERIDOS 2,6-DIISOPROPIL-FENIL ESTER DEL ACIDO [(2,4,6-TRIISOPROPIL-FENIL)-ACETIL]SULFAMICO, ACIDO 6,6'-OXIBIS(2,2-DIMETILHEXANOICO). LA COMPOSICION PUEDE SER UTIL PARA LOGRAR UN EFECTO DE DISLIPIDEMIA MEJORADA Y UN EFECTO DE SINDROME ISQUEMICO MEJORADOREFERS TO A COMPOSITION THAT INCLUDES a) A CARBOXIALKYLETER OF FORMULA (Y1) (R1) (R2) C- (CH2) nO- (CH2) mC (Y2) (R3) (R4) WHERE, n AND m ARE 2- 9; R1, R2, R3, R4 ARE C1-C6 ALKYL, C1-C6 ALKENYL, C1-C6 ALKYNYL, R1 AND R2 OR R3 AND R4 TOGETHER FORMING C3-C6 CARBOCICLE; Y1 AND Y2 ARE COOH, CHO, TETRAZOLE, COOR5; R5 IS C1-C5 ALKYL, C2-C6 ALKENYL, C2-C6 ALKYL; b) AN INHIBITOR OF THE ACETYL-COENZYME ENZYME A: CHOLESTEROL ACILTRANSFERASE (ACAT) THAT PREVENTS THE ABSORPTION OF DIETARY CHOLESTEROL IN THE BLOOD FLOW OR THE REABSORPTION OF CHOLESTEROL THAT HAS BEEN PREVIOUSLY RELEASED BY THE BODY ACROSS ACROSS ACTION ; OF FORMULA R1-X-S (= O) 2-NR-C (= O) -Y-R2; WHERE X AND Y ARE S, O; (CR'R ") n; n IS 1-4; R 'YR" ARE H, ALKYL, ALCOXY, HALOGEN, OH, ACILOXY, CYCLOALKYL, PHENYL R' AND R "FORM SPIROCYCLOALKYL, CARBONYL; ONE OF XEY IS (CR ' R ") n; YR 'YR "ARE H; n IS 1; R1 AND R2 ARE ARYL; R IS H, C1-C8 ALKYL, BENZYL; R1 AND R2 ARE PHENYL, PHENOXY, NAPHTHYL, ARYLALKYL, C1-C20 ALKYL, ADAMANTHYL, C3- CYCLOALKYL C6; PREFERRED COMPOUNDS 2,6-DIISOPROPYL-PHENYL ESTER OF SULFAMIC ACID [(2,4,6-TRIISOPROPYL-PHENYL) -ACETILE], 6,6'-OXIBIS (2,2-DIMETHYLHEXANOIC) ACID. THE COMPOSITION MAY BE USEFUL TO ACHIEVE AN IMPROVED DYSLIPIDEMIA EFFECT AND IMPROVED ISCHEMIC SYNDROME EFFECT

PE2001000517A 2000-06-07 2001-06-05 CARBOXIALKYLETER - ACAT INHIBITOR COMBINATIONS PE20020265A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21005600P 2000-06-07 2000-06-07

Publications (1)

Publication Number Publication Date
PE20020265A1 true PE20020265A1 (en) 2002-04-19

Family

ID=22781424

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000517A PE20020265A1 (en) 2000-06-07 2001-06-05 CARBOXIALKYLETER - ACAT INHIBITOR COMBINATIONS

Country Status (14)

Country Link
EP (1) EP1292363A2 (en)
JP (1) JP2003535125A (en)
AR (1) AR034255A1 (en)
AU (1) AU2001263003A1 (en)
BR (1) BR0111428A (en)
CA (1) CA2413906A1 (en)
GT (1) GT200100106A (en)
MX (1) MXPA02010762A (en)
PA (1) PA8518601A1 (en)
PE (1) PE20020265A1 (en)
SV (1) SV2002000466A (en)
TN (1) TNSN01085A1 (en)
UY (1) UY26752A1 (en)
WO (1) WO2001093845A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7387236B2 (en) 2001-10-09 2008-06-17 Delaware Capital Formation, Inc. Dispensing of currency

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762124B2 (en) * 1998-01-28 2003-06-19 Warner-Lambert Company Method for treating Alzheimer's disease

Also Published As

Publication number Publication date
GT200100106A (en) 2002-05-20
JP2003535125A (en) 2003-11-25
CA2413906A1 (en) 2001-12-13
EP1292363A2 (en) 2003-03-19
BR0111428A (en) 2003-06-10
AU2001263003A1 (en) 2001-12-17
PA8518601A1 (en) 2002-07-30
TNSN01085A1 (en) 2005-11-10
SV2002000466A (en) 2002-04-03
AR034255A1 (en) 2004-02-18
MXPA02010762A (en) 2003-03-10
WO2001093845A3 (en) 2002-10-10
WO2001093845A2 (en) 2001-12-13
UY26752A1 (en) 2001-07-31

Similar Documents

Publication Publication Date Title
ECSP045331A (en) Presentation form for oral administration, for 3? [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenylamino] -methyl} -1-methyl-1H-? Benzimidazole-5-carbonyl acid ethyl ester ) -pyridin-2-yl-amino] -propionic and its salts
AP2002002407A0 (en) Caspase inhibitors and uses thereof.
EA200300621A1 (en) BIARRYLIC DERIVATIVES OF NICOTINAMIDE, USEFUL AS AN INHIBITORS OF PDE4 ISOERMINENTS
CY1106901T1 (en) Substituted Indole Acid Derivative Derivatives as Inhibitor-1 Plasminogen Activator (PAI-1)
SE0400235D0 (en) New composition containing quinoline compounds
CY1109299T1 (en) Methanesulfonic SALT 3 - [(2 - {[4-hexyloxycarbonylamino-imino-methyl) -phenylamino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl ester and USE THIS AS MEDICINAL
PT998473E (en) MODIFICATION OF THE CRYSTAL FORM OF AN N-PHENYL-2-PYRIMIDINOAMINE DERIVATIVES PROCESSES FOR THEIR PREPARATION AND THEIR USE
HUP0002514A2 (en) Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
RU2008151757A (en) ORAL COMPOSITION CONTAINING 3- {5- [4- (CYCLOPENTYLOXY) -2-HYDROXYBENZOYL] -2 - [(3-HYDROXY-1, 2-BENZISOXAZOZOL-6-YL) METHOXY] Phenyl} Copyl
TR200003543T2 (en) The new 3-aryl-2-hydroxypropionic acid derivative III.
PE20020265A1 (en) CARBOXIALKYLETER - ACAT INHIBITOR COMBINATIONS
NO170938C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY EFFECTIVE PHOSPHONOSUBSTITUTED AMINOALKY ACIDS
CA2038409C (en) Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
EA200701181A1 (en) MEDICINES INTENDED FOR THE TREATMENT OR PREVENTION OF FIBROUS DISEASES
NO20053956L (en) Breast Cancer Resistance Protein (BCRP) Inhibitor
PE20011308A1 (en) COMPOSITION THAT INCLUDES AN ANTIHYPERTENSIVE AND A CARBOXIALKYLETER USEFUL TO TREAT VASCULAR DISEASES
CY1113162T1 (en) USE OF C- (2-FENYLO-CYCOLOXYL) -METHYLAMINE COMPOUNDS FOR PHARMACEUTICAL DISORDER TREATMENT
WO2002044130A1 (en) Substituted carboxylic acid derivatives
NO994386L (en) 2-substituted benzoylcycloalkyl-1-carboxylic acid derivatives
DE602004013658D1 (en) Couplers with 2,3,5-triaminopyridine structure and their use for dyeing keratin fibers
ATE353868T1 (en) PRODUCTION PROCESS FOR OPTICALLY PURE 2-(4-HYDROXYPHENOXY)-PROPIONIC ACID COMPOUNDS
UA95601C2 (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester-methanesulphonate and pharmaceutical composition comprising thereof
PE20030905A1 (en) WATER-SOLUBLE PENYLGLYCIN DERIVATIVES
NO20033880D0 (en) Process for the preparation of optically active propoxyaniline derivatives
RU2009138032A (en) NEW PREVENTIVE AND / OR MEDICINE AGAINST DIABETIC NEUROPATHY

Legal Events

Date Code Title Description
FC Refusal